How Do You Know If Your Patient Engagement Investment Is Working?

If our patient engagement investment stopped working tomorrow, how long would it take us to notice?

Ask a commercial leader how their patient support program is performing, and you will usually get a number. Enrollment is up. Activation rates are strong. First-fill conversion improved this quarter.

Then ask a harder question: are those patients still on therapy in month nine?

The room gets quieter.

This is not a failure of rigor. Pharma teams measure carefully and report diligently. The problem is that the metrics most organizations track were built to describe the first few weeks of a patient's experience — and almost nothing after that.

The metrics you have are 10% metrics

Enrollment counts. Prior authorization turnaround. Time to first fill. Activation rates. Copay card redemption.

Every one of these is a real number, and every one of them describes the same narrow window: the beginning. They tell you how efficiently a patient got started. They tell you nothing about whether that patient is still there.

This is the measurement expression of the 90/10 problem. Most patient support budgets concentrate on the 10% of the journey around initiation. Predictably, so do most patient support metrics. The instrumentation follows the investment, and both stop at roughly the same place.

The result is a strange kind of blindness. A program can post excellent numbers — high enrollment, fast time-to-fill, strong activation — while persistence quietly erodes in the months no one is measuring. The dashboard stays green. The revenue does not.

What the 90% actually requires you to see

Measuring the 90% means measuring duration, not conversion. Persistence rate. Time on therapy. Proportion of days covered. The point at which patients discontinue, and what preceded it.

These are harder metrics to build. They require longer observation windows, they cross data systems that were never designed to talk to each other, and they surface uncomfortable findings. But they are the only metrics that answer the question a commercial leader actually needs answered: is the money we are spending keeping patients on therapy?

Most organizations cannot answer that question today. Not because the data does not exist, but because it lives in pieces.

The fragmentation problem

Here is what makes this genuinely difficult, and why it is not solved by adding a metric to a dashboard.

The signals that would tell you whether patients are persisting are distributed across functions. Patient services holds the interaction data. Market access holds the coverage and abandonment data. Field teams hold what they hear from prescribers. Specialty pharmacy holds the refill behavior. Marketing holds the engagement data from the programs it funds.

Each function measures its own performance competently. None of them, alone, can see persistence — because persistence is not produced by any single function. It is produced by the handoffs between them, and the points of friction in those handoffs are precisely what no one owns and no one measures.

You cannot fix what you cannot see. And you cannot see across a system by looking harder at one part of it.

What a real answer looks like

A commercial leader who can actually answer "is our investment working?" has three things.

They know where in the journey patients are leaving — specifically, not directionally. They know which of those departure points are attributable to a gap in infrastructure rather than to the clinical realities of the therapy. And they know which of those gaps, if closed, would change the revenue trajectory most.

That is not a dashboard. It is a diagnostic — a structured view of where persistence leaks across functions, and what it costs at each point.

This is what the Gap Finder, our patent-pending diagnostic, was built to produce: a map of where persistence is being lost across the whole journey, made visible to every function at once, with the friction points named and prioritized.

Back to the question

For most organizations, the honest answer is several quarters. Enrollment would still look strong. Activation would still report green. The erosion would be happening in the months no one is instrumented to see, and it would surface eventually as a revenue number that no one could fully explain.

That delay is not a measurement inconvenience. It is the entire problem. By the time a persistence failure becomes visible in the numbers you track, the patients are already gone and the launch trajectory is already set.

The question is not whether your investment is working.

It is whether you would know.

Linked Patient Learning helps pharma teams see where patient persistence is lost — and what to build to hold it.